GlassScriptPhysician profile
Brandy Young
NPI 1184045957
$26,940.40
in general payments reported to CMS, 2019-2025
52 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $66.07 · 2022: $332 · 2023: $3,703 · 2024: $7,055 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,050 · Consulting Fee: $675 · Travel and Lodging: $281 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,436.51 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,050.00 |
| Consulting Fee | $675.00 |
| Travel and Lodging | $280.70 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $10,216.22 | 2023-2025 | |
| Ucb, INC. | $2,205.93 | 2023-2025 | Briviact, Fintepla, Rystiggo |
| Abbvie INC. | $1,576.79 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $1,355.77 | 2023-2025 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $746.87 | 2024-2025 | |
| Amgen INC. | $719.52 | 2023-2025 | Uplizna, Evenity, Repatha |
| Lundbeck LLC | $678.53 | 2023-2025 | Vyepti, Rexulti |
| Otsuka America Pharmaceutical, INC. | $573.38 | 2023-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $554.48 | 2023-2025 | Wainua, Lokelma, Tezspire |
| Sk Life Science, INC. | $546.84 | 2023-2025 | |
| Argenx US, INC. | $542.43 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Celgene Corporation | $487.20 | 2023-2025 | Zeposia |
| Novo Nordisk INC | $483.76 | 2021-2025 | Wegovy |
| Biogen, INC. | $448.56 | 2023-2025 | Leqembi, Vumerity, Tysabri |
| Alnylam Pharmaceuticals INC. | $386.19 | 2023-2025 | Amvuttra |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $371.67 | 2023-2025 | Hyqvia, Gammagard |
| Lilly USA, LLC | $307.84 | 2023-2025 | Amyvid, Emgality, Kisunla |
| Teva Pharmaceuticals USA, INC. | $307.18 | 2023-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Acorda Therapeutics, INC | $289.54 | 2023-2024 | Inbrija |
| Acadia Pharmaceuticals INC | $286.91 | 2024-2025 | Nuplazid |
| Eisai INC. | $268.38 | 2023-2025 | |
| Horizon Therapeutics Plc | $258.72 | 2023 | Uplizna, Krystexxa |
| Catalyst Pharmaceuticals, INC. | $231.64 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $226.37 | 2023-2025 | Ultomiris, Soliris |
| Emd Serono, INC. | $219.08 | 2024-2025 | |
| Csl Behring | $211.47 | 2024-2025 | Hizentra |
| Grifols USA, LLC | $210.79 | 2023-2025 | Gamunex-C |
| Genentech USA, INC. | $197.03 | 2025 | Ocrevus, Ocrevus Zunovo |
| Gilead Sciences, INC. | $170.21 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $164.43 | 2023-2024 | Acthar |
| Axsome Therapeutics, INC. | $154.88 | 2025 | Symbravo |
| Octapharma USA, INC. | $141.31 | 2023-2025 | Panzyga |
| Paratek Pharmaceuticals, INC. | $138.03 | 2023-2024 | Nuzyra |
| E.R. Squibb & Sons, L.L.C. | $133.67 | 2025 | Zeposia |
| Janssen Biotech, INC. | $117.61 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.91 | 2022 | |
| Amneal Pharmaceuticals LLC | $99.84 | 2023-2024 | Crexont, Rytary |
| Axonics, INC. | $94.56 | 2024 | Axonics |
| Radius Health, INC. | $91.27 | 2025 | Tymlos |
| Tg Therapeutics, INC. | $90.47 | 2024-2025 | |
| Scilex Pharmaceuticals INC. | $84.91 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $82.16 | 2024-2025 | Ponvory, Fanapt |
| Aucta Pharmaceuticals, INC. | $61.25 | 2025 | Motpoly Xr |
| Tanabe Pharma America, INC. | $60.91 | 2023-2025 | Radicava |
| Ani Pharmaceuticals, INC. | $51.02 | 2024 | Purified Cortrophin Gel |
| Jazz Pharmaceuticals INC. | $47.79 | 2023-2024 | Epidiolex |
| Neurelis, INC. | $40.09 | 2025 | Valtoco |
| Azurity Pharmaceuticals, INC. | $27.01 | 2023 | Horizant |
| Xeris Pharmaceuticals, INC. | $21.99 | 2023 | Keveyis |
| Amylyx Pharmaceuticals, INC. | $21.64 | 2023 | Relyvrio |
| Genzyme Corporation | $17.55 | 2025 | |
| Philips North America LLC | $14.80 | 2024 | (Cm9) Amb Mon & Diag Und |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.